{"id":"https://openalex.org/W3015094841","doi":"https://doi.org/10.1007/s40259-020-00422-1","title":"The Path Towards a Tailored Clinical Biosimilar Development","display_name":"The Path Towards a Tailored Clinical Biosimilar Development","publication_year":2020,"publication_date":"2020-04-07","ids":{"openalex":"https://openalex.org/W3015094841","doi":"https://doi.org/10.1007/s40259-020-00422-1","mag":"3015094841","pmid":"https://pubmed.ncbi.nlm.nih.gov/32266678","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7211192"},"language":"en","primary_location":{"id":"doi:10.1007/s40259-020-00422-1","doi":"https://doi.org/10.1007/s40259-020-00422-1","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40259-020-00422-1","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40259-020-00422-1.pdf","source":{"id":"https://openalex.org/S143194599","display_name":"BioDrugs","issn_l":"1172-7039","issn":["1172-7039","1173-8804","1179-190X","2195-8351"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BioDrugs","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40259-020-00422-1.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038173861","display_name":"Martin Schiestl","orcid":"https://orcid.org/0000-0001-5784-9951","observed_orcids":["https://orcid.org/0000-0001-5784-9951"]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Martin Schiestl","raw_affiliation_strings":["Sandoz GmbH, Biochemiestrasse 10, 6336, Langkampfen, Austria. martin.schiestl@sandoz.com","Sandoz GmbH, Biochemiestrasse 10, 6336, Langkampfen, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sandoz GmbH, Biochemiestrasse 10, 6336, Langkampfen, Austria. martin.schiestl@sandoz.com","institution_ids":["https://openalex.org/I4388891806"]},{"raw_affiliation_string":"Sandoz GmbH, Biochemiestrasse 10, 6336, Langkampfen, Austria","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086610054","display_name":"Gopinath M. Ranganna","orcid":"https://orcid.org/0000-0001-9974-3354","observed_orcids":["https://orcid.org/0000-0001-9974-3354"]},"institutions":[{"id":"https://openalex.org/I4405260856","display_name":"Bengaluru City University","ror":"https://ror.org/04cpe8e53","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405260856"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Gopinath Ranganna","raw_affiliation_strings":["Mylan Pharm. Private Ltd., Bengaluru, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mylan Pharm. Private Ltd., Bengaluru, India","institution_ids":["https://openalex.org/I4405260856"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Keith Watson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158021","display_name":"Celltrion (South Korea)","ror":"https://ror.org/05k84m754","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158021"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Keith Watson","raw_affiliation_strings":["Celltrion Inc., Incheon, Republic of Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celltrion Inc., Incheon, Republic of Korea","institution_ids":["https://openalex.org/I4210158021"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045727177","display_name":"Byoungin Jung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405271353","display_name":"Samsung Bioepis (South Korea)","ror":"https://ror.org/02a6d4p26","country_code":"KR","type":"company","lineage":["https://openalex.org/I4405271353"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Byoungin Jung","raw_affiliation_strings":["Samsung Bioepis Co. Ltd., Incheon, Republic of Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Samsung Bioepis Co. Ltd., Incheon, Republic of Korea","institution_ids":["https://openalex.org/I4405271353"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066554507","display_name":"Karsten Roth","orcid":"https://orcid.org/0000-0002-9041-0227","observed_orcids":["https://orcid.org/0000-0002-9041-0227"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karsten Roth","raw_affiliation_strings":["Polpharma Biologics S.A., Warsaw, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Polpharma Biologics S.A., Warsaw, Poland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033640724","display_name":"Bj\u00f6rn Capsius","orcid":"https://orcid.org/0009-0000-4477-6255","observed_orcids":["https://orcid.org/0009-0000-4477-6255"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bj\u00f6rn Capsius","raw_affiliation_strings":["Formycon AG, Martinsried, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Formycon AG, Martinsried, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060282329","display_name":"Michael Trieb","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Trieb","raw_affiliation_strings":["bioeq GmbH, Holzkirchen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bioeq GmbH, Holzkirchen, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025919221","display_name":"Peter Bias","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139694","display_name":"Teva Pharmaceuticals (Germany)","ror":"https://ror.org/03xa4xh46","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210109720","https://openalex.org/I4210139694"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Peter Bias","raw_affiliation_strings":["Teva Pharm. Ind. Ltd., Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Teva Pharm. Ind. Ltd., Ulm, Germany","institution_ids":["https://openalex.org/I4210139694"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083184451","display_name":"Julie Mar\u00e9chal-Jamil","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julie Mar\u00e9chal-Jamil","raw_affiliation_strings":["IGBA, Geneva, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IGBA, Geneva, Switzerland","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5038173861"],"corresponding_institution_ids":["https://openalex.org/I4388891806"],"apc_list":{"value":3860,"currency":"USD","value_usd":3860},"apc_paid":{"value":3860,"currency":"USD","value_usd":3860},"fwci":0.9738,"has_fulltext":true,"cited_by_count":75,"citation_normalized_percentile":{"value":0.72202899,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"34","issue":"3","first_page":"297","last_page":"306"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13417","display_name":"Biomedical Ethics and Regulation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.9300000071525574},{"id":"https://openalex.org/keywords/biosimilar-approval","display_name":"biosimilar approval","score":0.8330000042915344},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9330000281333923},{"id":"https://openalex.org/keywords/process-related-impurities","display_name":"process-related impurities","score":0.7699999809265137},{"id":"https://openalex.org/keywords/regulatory-standards","display_name":"regulatory standards","score":0.6769999861717224},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.9945311546325684},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6871147751808167},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5695580840110779},{"id":"https://openalex.org/C2777589142","wikidata":"https://www.wikidata.org/wiki/Q6770899","display_name":"Marketing authorization","level":2,"score":0.49316519498825073},{"id":"https://openalex.org/C108759981","wikidata":"https://www.wikidata.org/wiki/Q788590","display_name":"Authorization","level":2,"score":0.47992950677871704},{"id":"https://openalex.org/C2781234862","wikidata":"https://www.wikidata.org/wiki/Q6543077","display_name":"Licensure","level":2,"score":0.4574737548828125},{"id":"https://openalex.org/C2910001868","wikidata":"https://www.wikidata.org/wiki/Q458","display_name":"European union","level":2,"score":0.4266124963760376},{"id":"https://openalex.org/C2992053201","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Clinical efficacy","level":2,"score":0.41771864891052246},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3462964594364166},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33214813470840454},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.21944564580917358},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.14831477403640747},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.14276185631752014},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.1396898627281189},{"id":"https://openalex.org/C509550671","wikidata":"https://www.wikidata.org/wiki/Q126945","display_name":"Medical education","level":1,"score":0.13684403896331787},{"id":"https://openalex.org/C155202549","wikidata":"https://www.wikidata.org/wiki/Q178803","display_name":"International trade","level":1,"score":0.08662170171737671},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000076722","descriptor_name":"Drug Development","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D005062","descriptor_name":"European Union","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40259-020-00422-1","doi":"https://doi.org/10.1007/s40259-020-00422-1","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40259-020-00422-1","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40259-020-00422-1.pdf","source":{"id":"https://openalex.org/S143194599","display_name":"BioDrugs","issn_l":"1172-7039","issn":["1172-7039","1173-8804","1179-190X","2195-8351"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BioDrugs","raw_type":"journal-article"},{"id":"pmid:32266678","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32266678","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7211192","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7211192/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BioDrugs","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s40259-020-00422-1","doi":"https://doi.org/10.1007/s40259-020-00422-1","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40259-020-00422-1","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40259-020-00422-1.pdf","source":{"id":"https://openalex.org/S143194599","display_name":"BioDrugs","issn_l":"1172-7039","issn":["1172-7039","1173-8804","1179-190X","2195-8351"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BioDrugs","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.8999999761581421,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320333100","display_name":"Sandoz","ror":null}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3015094841.pdf","grobid_xml":"https://content.openalex.org/works/W3015094841.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1821162804","https://openalex.org/W2008138329","https://openalex.org/W2023749561","https://openalex.org/W2051129711","https://openalex.org/W2077285487","https://openalex.org/W2078172351","https://openalex.org/W2290587826","https://openalex.org/W2581281042","https://openalex.org/W2587046531","https://openalex.org/W2607161983","https://openalex.org/W2615381962","https://openalex.org/W2762518907","https://openalex.org/W2763537431","https://openalex.org/W2768717631","https://openalex.org/W2793866077","https://openalex.org/W2810109928","https://openalex.org/W2937963956","https://openalex.org/W2950815632","https://openalex.org/W2966736720","https://openalex.org/W2973908960","https://openalex.org/W2982345450","https://openalex.org/W3004335124"],"related_works":["https://openalex.org/W2791210100","https://openalex.org/W2997919870","https://openalex.org/W2080182246","https://openalex.org/W4385606592","https://openalex.org/W2608742892","https://openalex.org/W2023488801","https://openalex.org/W2796520488","https://openalex.org/W7203686400","https://openalex.org/W4243877896","https://openalex.org/W2594434774"],"abstract_inverted_index":{"Since":[0],"the":[1,14,32,35,42,47,58,78,86,97,109,132,157,161,178,184,195,231,251,255,258],"first":[2],"approval":[3,40],"of":[4,13,18,34,57,73,75,91,122,134,147,173,177,181,186,222,233,241],"a":[5,187],"biosimilar":[6,19,39,98,118,192,234,247],"medicinal":[7],"product":[8],"in":[9,41,69,103,125,156,160,209,230,254],"2006,":[10],"scientific":[11],"understanding":[12],"features":[15],"and":[16,31,112,131,144,190,205,225,239,257],"development":[17,29,179,193],"medicines":[20],"has":[21],"accumulated.":[22],"This":[23,175,214],"review":[24,176],"scrutinizes":[25],"public":[26],"information":[27],"on":[28],"programs":[30,59],"contribution":[33],"clinical":[36,80,101,114,123,171,200],"studies":[37,82,115,204],"for":[38,198],"European":[43],"Union":[44],"(EU)":[45],"and/or":[46,65,202],"United":[48],"States":[49],"(US)":[50],"until":[51],"November":[52],"2019.":[53],"The":[54,237],"retrospective":[55],"evaluation":[56],"that":[60,68,105,152],"eventually":[61],"obtained":[62],"marketing":[63],"authorization":[64],"licensure":[66],"revealed":[67],"95%":[70],"(36":[71],"out":[72,90],"38)":[74],"all":[76,223],"programs,":[77],"comparative":[79,199],"efficacy":[81,95,201],"confirmed":[83],"similarity.":[84],"In":[85],"remaining":[87],"5%":[88],"(2":[89],"38),":[92],"despite":[93],"meeting":[94],"outcomes,":[96],"candidates":[99,151],"exhibited":[100],"differences":[102,124],"immunogenicity":[104,126],"required":[106],"changes":[107],"to":[108,116,129,141,167,246],"manufacturing":[110],"process":[111],"additional":[113],"enable":[117],"approval.":[119],"Both":[120],"instances":[121],"occurred":[127],"prior":[128],"2010,":[130],"recurrence":[133],"these":[135],"cases":[136],"is":[137,216],"unlikely":[138],"today":[139],"due":[140,166],"state-of-the-art":[142],"assays":[143],"improved":[145],"control":[146],"process-related":[148],"impurities.":[149],"Biosimilar":[150],"were":[153,163],"neither":[154],"approved":[155,165],"EU":[158,256],"nor":[159],"US":[162],"not":[164],"reasons":[168],"other":[169],"than":[170],"confirmation":[172],"efficacy.":[174,213],"history":[180],"biosimilars":[182],"allows":[183],"proposal":[185,215],"more":[188],"efficient":[189],"expedited":[191],"without":[194,206],"routine":[196],"need":[197],"pharmacodynamic":[203],"any":[207],"compromise":[208],"quality,":[210],"safety,":[211],"or":[212],"scientifically":[217],"valid,":[218],"consistent":[219],"with":[220],"regulation":[221],"biologics,":[224],"maintains":[226],"robust":[227],"regulatory":[228,252],"standards":[229,253],"assessment":[232],"candidates.":[235],"Note:":[236],"findings":[238],"conclusion":[240],"this":[242],"paper":[243],"are":[244],"limited":[245],"products":[248],"developed":[249],"against":[250],"US.":[259]},"counts_by_year":[{"year":2026,"cited_by_count":16},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2020-04-10T00:00:00"}